Home・Elenco Azioni・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Aperta

SettoreSettore sanitario

80.86 -0.33

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

79.94

Massimo

81.55

Metriche Chiave
By Trading Economics
Entrata	11M -156M
Vendite	28M 222M
EPS	-0.78
Margine di Profitto	-70.082
Dipendenti	999
EBITDA	-24M -137M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.2% upside

Dividendi
By Acuity
Utili prossimi	28 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-981M 16B
Apertura precedente	81.19
Chiusura precedente	80.86

Notizie sul Sentiment di mercato

By Acuity

38%

62%

110 / 340 Classifica in Healthcare

Bridgebio Pharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 ago 2026, 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19 ago 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18 ago 2026, 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14 ago 2026, 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13 ago 2026, 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12 ago 2026, 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11 ago 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10 ago 2026, 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7 ago 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6 ago 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5 ago 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4 ago 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3 ago 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31 lug 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30 lug 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29 lug 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28 lug 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27 lug 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Confronto tra pari

Modifica del prezzo

Bridgebio Pharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

33.2% in crescita

Previsioni per 12 mesi

Media 108.56 USD 33.2%

Alto 157 USD

Basso 94 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bridgebio Pharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 17 che hanno fornito valutazioni azionarie a Bridgebio Pharma Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

110 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.